---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-316919"
form_type: "8-K"
ticker: "CERS"
cik: "0001020214"
company_name: "CERUS CORP"
filed_at: "2021-11-02T23:59:59+00:00"
generated_at: "2026-06-28T14:49:10.554174+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cerus Q3 product revenue $36.1M (+53% YoY); raises FY21 guidance to $127-129M

## Summary
- Total revenue $42.1M (+44% YoY); product revenue $36.1M (+53% YoY) driven by U.S. INTERCEPT platelet adoption.
- Net loss $12.4M ($0.07/shr) improved from $14.1M ($0.08/shr) in Q3 2020.
- Product gross margin 51.3% vs 53.6% YoY; gross profit record $18.5M.
- FY21 product revenue guidance raised to $127-129M (from $118-122M), representing 38-40% growth.
- Cash and short-term investments $120.0M at Sept 30; $55M notes due, $10M revolver drawn.

## SEC filing metadata
- accession: 0001193125-21-316919
- form_type: 8-K
- ticker: CERS
- cik: 0001020214
- company_name: CERUS CORP
- filed_at: 2021-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1020214/000119312521316919/0001193125-21-316919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1020214/000119312521316919/d220853d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-316919
- JSON: https://secwatch.observer/filing/0001193125-21-316919.json
- Plain text: https://secwatch.observer/filing/0001193125-21-316919.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.